BioSenic patent granted in Canada for broader protection of ATO therapeutic platform

BioSenic patent granted in Canada for broader protection of ATO therapeutic platform

PRESS RELEASE – INSIDE INFORMATION    BioSenic patent granted in Canada for broader protection of its ATO therapeutic platform Composition-of-matter patent covers the therapeutic use of arsenic salts and metal ions through various routes of administration. Enriched IP portfolio protects arsenic trioxide (ATO) use combined with copper ions delivery, which has demonstrated increased therapeutic potential … Read more

ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer’s Disease

ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer’s Disease

Research demonstrated that activation of the inflammasome/ASC speck pathway has a vital role in synaptic degeneration in Alzheimer’s Disease (AD). ZyVersa is developing IC 100, a monoclonal antibody targeting inflammasome ASC specks to block initiation and perpetuation of damaging inflammation in the central nervous system and peripheral tissues. WESTON, Fla., Jan. 24, 2024 (GLOBE NEWSWIRE) … Read more